TRDA

Entrada Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1689375Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$25.0M

Net Income FY2025

$(144.0M)

EPS (Basic, as reported)

$-3.47

Net Margin FY2025

-565.5%

ROE FY2025

-47.0%

Total Equity

$306.0M

Shares Out

39M

Business description

Entrada Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 129 → 25 -56% CAGR

Fiscal yearFY2020⚑FY2021⚑FY2022FY2023FY2024FY2025

Revenue———12921125

Research & development(21)(36)(67)(100)(125)(142)

General & administrative(6)(15)(31)(32)(38)(41)

Total operating expenses(27)(51)(97)(132)(164)(183)

Operating income(27)(51)(97)(3)47(158)

Other income (expense), net003151915

Income tax expense000(19)(1)(1)

Net income(27)(51)(95)(7)66(144)

EPS — basic($24.00)($8.16)($3.02)($0.20)$1.76($3.47)

EPS — diluted($24.00)($8.16)($3.02)($0.20)$1.68($3.47)

Shares outstanding — basic (M)1631333741

Shares outstanding — diluted (M)1631333941

⚑ Weighted-average shares changed ×6.00 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×5.17 between FY2021 and FY2022 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.